3 Underperforming Pharma Stocks Trying to Bounce Back

Analysts have very high price targets on MRNS

Sep 26, 2019 at 10:49 AM
facebook twitter linkedin

This morning we're looking at Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), and Marinus Pharmaceuticals Inc (NASDAQ:MRNS). All three pharma stocks have had a difficult time on the charts, but today the shares are trying to rebound. Let's dig in to the shares of ALXN, RIGL, and MRNS.

For ALXN, William Blair began coverage with an "outperform" rating and $146 fair value price. This comes after the stock has been stuck in a series of lower highs and lows since the April peak near $141, but the round $100 level could now be acting as support, with the shares last seen at $100.26. Either way, most analysts are still bullish, with 12 of 15 recommending to buy the shares.

RIGL, meanwhile, is up 8.8% at $1.86, after J.P. Morgan Securities upped its price target to $7 from $6 and kept is "overweight" rating in place, citing the company's blood disorder drug Tavalisse. The brokerage firm believes the treatment could bring in more than $11 million in the third quarter and nearly $13 million in the fourth quarter. Despite today's rise, the shares are down almost 25% in the past three months, and are still staring up at their 50-day moving average.

Finally, MRNS is exploding 37.2% higher to $1.88, thanks to news the company's seizure treatment Ganaxolone met its main goals in a phase 2 study. This has the equity above its 50-day moving average for the first time since the massive July bear gap, though the stock's year-over-year deficit remains at more than 80%. Analysts are still betting Marinus Pharmaceuticals can rebound in a big way, since the average 12-month price target is $6.88.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!



Special Offers from Schaeffer's Trading Partners